Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann N Y Acad Sci. 2012 Dec;1275:13-6. doi: 10.1111/j.1749-6632.2012.06825.x.

Further developments with antisense treatment for myasthenia gravis.

Author information

  • 1Greater Manchester Neuroscience Centre, Manchester UK. jon.sussman@manchester.ac.uk

Abstract

We present further developments in the study of the antisense oligonucleotide EN101. Ongoing in vitro and in vivo studies demonstrate that EN101 is a TLR9-specific ligand that can suppress pro-inflammatory functions and shift nuclear factor kappa B (NF-κB) from the pro-inflammatory canonical pathway to the anti-inflammatory alternative pathway, which results in decreases acetylcholinesterase (AChE) activity. Preliminary results of a double-blinded phase II cross-over study compared 10, 20, and 40 mg EN101 administered to patients with myasthenia gravis. Patients were randomly assigned to one of three treatment groups in weeks 1, 3, and 5 and received their pretreatment dose of pyridostigmine in weeks 2 and 4. Thus far, all doses show a decrease in QMG scores, with a greater response to higher doses.

© 2012 New York Academy of Sciences.

PMID:
23278572
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk